{"id":4833,"date":"2025-06-24T23:02:39","date_gmt":"2025-06-24T23:02:39","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2025\/06\/24\/top-fda-drug-regulator-jacqueline-corrigan-curay-town-hall-retirement-mike-davis-cder-deputy-director\/"},"modified":"2025-06-24T23:02:39","modified_gmt":"2025-06-24T23:02:39","slug":"top-fda-drug-regulator-jacqueline-corrigan-curay-town-hall-retirement-mike-davis-cder-deputy-director","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2025\/06\/24\/top-fda-drug-regulator-jacqueline-corrigan-curay-town-hall-retirement-mike-davis-cder-deputy-director\/","title":{"rendered":"STAT+: Top FDA drug regulator tells staff much is still in flux, as she prepares to retire"},"content":{"rendered":"

STAT+: Top FDA drug regulator tells staff much is still in flux, as she prepares to retire
\n \t

\n
<\/BR>
\n
\n \t

\n
<\/BR><\/p>\n

\n

WASHINGTON \u2014 Outgoing Food and Drug Administration regulator Jacqueline Corrigan-Curay acknowledged to staff that much is still in flux at the agency, weeks before she retires<\/a>.<\/p>\n

\u201cWe are leaner and therefore we have to find ways to be efficient and do things in new ways,\u201d she told staff, according to a recording of a town hall meeting obtained by STAT.\u00a0<\/p>\n

She did not say who will be the next leader of the Center for Drug Evaluation and Research once she retires next month. Her retirement is the latest in a series of departures of senior officials<\/a> at the FDA, who have either chosen to take early retirements, left for other jobs, or been forced out by political appointees.<\/p>\n

Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n

\t

\n
<\/BR>
\n Lizzy Lawrence
\n \t

\n
<\/BR>
\nGo to statnews<\/a>
\n \t

\n
<\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"

STAT+: Top FDA drug regulator tells staff much is still in flux, as she prepares to retire WASHINGTON \u2014 Outgoing Food and Drug Administration regulator Jacqueline Corrigan-Curay acknowledged to staff that much is still in flux at the agency, weeks before she retires. \u201cWe are leaner and therefore we have to find ways to be […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2181,2146,2176,2155,2151,2144,2152],"tags":[2150],"class_list":["post-4833","post","type-post","status-publish","format-standard","hentry","category-exclusive","category-fda","category-pharma","category-pharmaceuticals","category-policy","category-politics","category-stat","tag-statnews"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/4833"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=4833"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/4833\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=4833"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=4833"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=4833"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}